ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Deferred Revenue of -$169.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$81.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$88.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$122.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$419.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2025 was -$19.82M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2024 was -$119.81M, a 185.59% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2023 was $139.98M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$169.00K 10-Q · filed 2026-08-05 | -$291.00K derived: sum of 3 quarters · filed 2026-08-05 | -$710.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$88.00K 10-Q · filed 2026-05-07 | -$210.00K derived: sum of 2 quarters · filed 2026-05-07 | -$629.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$541.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.31M derived: sum of 3 quarters · filed 2026-08-05 | -$19.82M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$419.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.19M derived: sum of 2 quarters · filed 2026-08-05 | -$19.70M 10-Q · filed 2025-11-06 | -$53.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$770.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$19.28M 10-Q · filed 2026-08-05 | -$53.00M derived: sum of 3 quarters · filed 2026-08-05 | -$69.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$18.51M 10-Q · filed 2026-05-07 | -$52.23M derived: sum of 2 quarters · filed 2026-05-07 | -$69.20M derived: sum of 3 quarters · filed 2026-05-07 | -$156.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$33.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$50.68M derived: sum of 2 quarters · filed 2026-02-26 | -$137.70M derived: sum of 3 quarters · filed 2026-02-26 | -$119.81M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$16.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$103.99M derived: sum of 2 quarters · filed 2025-11-06 | -$86.09M 10-Q · filed 2025-11-06 | -$105.06M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$87.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$69.13M 10-Q · filed 2025-08-06 | -$88.10M derived: sum of 3 quarters · filed 2025-08-06 | -$126.31M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $17.89M 10-Q · filed 2025-05-08 | -$1.07M derived: sum of 2 quarters · filed 2025-05-08 | -$39.28M derived: sum of 3 quarters · filed 2025-05-08 | -$53.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$18.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$57.18M derived: sum of 2 quarters · filed 2025-02-27 | -$71.61M derived: sum of 3 quarters · filed 2025-02-27 | $139.98M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$38.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$52.64M derived: sum of 2 quarters · filed 2024-11-05 | $158.95M 10-Q · filed 2024-11-05 | $158.95M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$14.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $197.16M 10-Q · filed 2024-08-13 | $197.16M derived: sum of 3 quarters · filed 2024-08-13 | $197.16M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $211.58M 10-Q · filed 2024-05-07 | $211.58M derived: sum of 2 quarters · filed 2024-05-07 | $211.58M derived: sum of 3 quarters · filed 2024-05-07 | $211.58M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |